Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px
Document › Details

Allecra Therapeutics GmbH. (4/3/18). "Press Release: Allecra Therapeutics Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10,2018". Lörrach & Saint Louis.

Region Region Monaco
Organisations Organisation Allecra Therapeutics GmbH
  Group Allecra Therapeutics (Group)
  Organisation 2 H.C. Wainwright & Co. LLC
  Group H.C. Wainwright (Group)
Products Product H.C. Wainwright Global Life Sciences Conference 2018 Monaco
  Product 2 antibiotic
Index term Index term Allecra Therapeutics–HC Wainwright: investor conference, 201804 supply service Allecra presents at HC Wainwright Global Life Sciences Conference
Person Person Benedict, Nicholas (Allecra Therapeutics 201304 CEO + Co-Founder)
     


Allecra Therapeutics (Private), today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Nicholas Benedict, co-founder and chief executive officer of Allecra Therapeutics, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event: H. C. Wainwright Annual Global Life Sciences Conference
Date: April 10, 2018 Time: 15:25-15:50h (Central European Time)
Location: Salon Atlantique - Est (2nd Floor)]; Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco

The presentation will be webcast live. To access the webcast, please visit http://wsw.com/webcast/hcw2/altg The webcast replay will remain available for 90 days following the live presentation.

- Ends -


For further information please contact

Allecra Therapeutics GmbH
Nicholas Benedict
+41 79 592 2005 / info@allecra.com


About Allecra Therapeutics

Allecra Therapeutics, established in 2013, is a clinical stage biopharmaceutical company dedicated to the development of novel treatments to combat multi drug-resistant Gram-negative bacterial infections. Its lead product candidate, Cefepime/AAI101, a novel Extended Spectrum ß-lactamase inhibitor designed to overcome resistance of typical Gram-negative hospital pathogens harboring Extended Spectrum ßlactamases (ESBLs), holds Qualified Infectious Disease Product (QIDP) status and has been granted Fast Track Designation by the FDA, for use in complicated urinary tract infections (cUTI), complicated intraabdominal infections (cIAI) and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP).

Allecra has completed Phase 2 clinical trials for the treatment of multi-drug-resistant Gram-negative bacterial infections in the hospital.

Allecra’s mission is to contribute towards the global effort to combat antibiotic resistance by developing new treatments which overcome emerging resistance mechanisms, thereby saving lives of patients whose infections may otherwise be inadequately treated.

Allecra is supported by existing investors Forbion, Delos Capital, EdRIP, Xeraya Capital, EMBL Ventures, BioMed Partners and Nicholas Benedict. Allecra’s wholly-owned French subsidiary is a beneficiary of financial support from the French public bank Bpifrance and from the Région Alsace.

For more information on Allecra please visit www.allecra.com or email info@allecra.com.

   
Record changed: 2018-04-08

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px

More documents for Allecra Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px